手握阿斯利康重磅交易,国产减肥药“黑马”冲击港交所

健识局
Oct 14

一家手握重磅BD的生物医药企业,正在冲刺港股。10月8日,诚益生物向港交所提交上市申请。这家公司做口服小分子GLP-1减肥药,2023年11月授权给了阿斯利康,拿到首付款1.85亿美元,总里程碑付款最高达到18.25亿美元。国内开发GLP-1的企业不少,能拿到这样大笔金额BD的却不多。诚益生物的创始人和科学顾问都曾任职于礼来,有着丰富的代谢类药物研发经验。IPO前,诚益生物的估值已经接近5亿美元。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10